Guidance for Healthcare Providers on Newest Guidelines for Over-the-Counter Drug Treatment of Mild Symptoms of COVID-19

Am J Med. 2024 Jun;137(6):490-493. doi: 10.1016/j.amjmed.2024.03.003. Epub 2024 Mar 13.

Abstract

On January 18, 2024, the US Centers for Disease Control and Prevention issued their most recent guidelines for over-the-counter drugs for coronavirus disease 2019 (COVID-19). Specifically, the organization stated that "Most people with COVID-19 have mild illness and can recover at home. You can treat symptoms with over-the-counter medicines, such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil), to help you feel better." In this review we consider the contributions of different types of evidence and conclude that healthcare providers should make individual clinical judgments for each of their patients in the selection of over-the-counter drugs to treat symptoms of COVID-19. This judgment should be based on the entire benefit to risk profile of the patient. It is our belief that the individual healthcare provider knows far more about each of his or her patients than anyone, including expert members of guideline committees. Their astute and judicious individual clinical decision-making for each individual patient based on all these considerations has the potential to do far more good than harm.

Keywords: COVID-19; Cardiovascular; Gastrointestinal; Guidance; Guidelines; Mild Symptoms, Over-the-Counter Drugs; Treatment.

Publication types

  • Review

MeSH terms

  • COVID-19
  • COVID-19 Drug Treatment*
  • Health Personnel
  • Humans
  • Nonprescription Drugs* / therapeutic use
  • Practice Guidelines as Topic*
  • SARS-CoV-2
  • Severity of Illness Index
  • United States

Substances

  • Nonprescription Drugs